Evidence map›Paper›PMID 30279361›Full record

ArticleInternational journal of molecular sciences2018

Effects of 1-Methyltryptophan on Immune Responses and the Kynurenine Pathway after Lipopolysaccharide Challenge in Pigs.

Elisa Wirthgen, Winfried Otten, Margret Tuchscherer, Armin Tuchscherer, Grazyna Domanska, Julia Brenmoehl, Juliane Günther, Daniela Ohde, Werner Weitschies, Anne Seidlitz and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Elisa WirthgenInstitute of Behavioural Physiology, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany. elisa.wirthgen@googlemail.com.
Winfried OttenInstitute of Behavioural Physiology, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany. otten@fbn-dummerstorf.de.ORCID 0000-0002-5613-5356
Margret TuchschererInstitute of Behavioural Physiology, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany. mtuchsch@fbn-dummerstorf.de.
Armin TuchschererInstitute of Genetics and Biometry, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany. atuchsch@fbn-dummerstorf.de.
Grazyna DomanskaInstitute of Immunology and Transfusion Medicine, University of Greifswald, D-17475 Greifswald, Germany. grazyna.domanska@uni-greifswald.de.
Julia BrenmoehlInstitute of Genome Biology, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany. brenmoehl@fbn-dummerstorf.de.
Juliane GüntherInstitute of Genome Biology, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany. j.guenther@fbn-dummerstorf.de.ORCID 0000-0002-6190-5044
Daniela OhdeInstitute of Genome Biology, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany. ohde@fbn-dummerstorf.de.
Werner WeitschiesInstitute of Pharmacy, University of Greifswald, D-17489 Greifswald, Germany. werner.weitschies@uni-greifswald.de.
Anne SeidlitzInstitute of Pharmacy, University of Greifswald, D-17489 Greifswald, Germany. anne.seidlitz@uni-greifswald.de.
Eberhard ScheuchInstitute of Pharmacology, University of Greifswald, D-17489 Greifswald, Germany. scheuch@uni-greifswald.de.
Ellen KanitzInstitute of Behavioural Physiology, Leibniz Institute for Farm Animal Biology (FBN), D-18196 Dummerstorf, Germany. ellen.kanitz@fbn-dummerstorf.de.
Research Institute for Farm Animal Biology (FBN) · DEUniversität Greifswald · DEUniversitätsmedizin Greifswald · DE

Funding

Deutsche Forschungsgemeinschaft KA 1266/5-1, SCHU 853/7-1
6 · The paper itself

Abstract

An enhanced indoleamine 2,3-dioxygenase 1 (IDO1) activity is associated with an increased mortality risk in sepsis patients. Thus, the preventive inhibition of IDO1 activity may be a promising strategy to attenuate the severity of septic shock. 1-methyltryptophan (1-MT) is currently in the interest of research due to its potential inhibitory effects on IDO1 and immunomodulatory properties. The present study aims to investigate the protective and immunomodulatory effects of 1-methyltryptophan against endotoxin-induced shock in a porcine in vivo model. Effects of 1-MT were determined on lipopolysaccharide (LPS)-induced tryptophan (TRP) degradation, immune response and sickness behaviour. 1-MT increased TRP and its metabolite kynurenic acid (KYNA) in plasma and tissues, suppressed the LPS-induced maturation of neutrophils and increased inactivity of the animals. 1-MT did not inhibit the LPS-induced degradation of TRP to kynurenine (KYN)-a marker for IDO1 activity-although the increase in KYNA indicates that degradation to one branch of the KYN pathway is facilitated. In conclusion, our findings provide no evidence for IDO1 inhibition but reveal the side effects of 1-MT that may result from the proven interference of KYNA and 1-MT with aryl hydrocarbon receptor signalling. These effects should be considered for therapeutic applications of 1-MT.

Indexed as

Metabolic Networks and PathwaysAnimalsCytokinesFibroblastsImmunityInflammationKynurenineLipopolysaccharidesLungMetabolomeRNA, MessengerSwineTryptophan1-methyltryptophanCytokinesKynurenineLipopolysaccharidesRNA, MessengerTryptophanindoleamine 2,3-dioxygenasekynurenine pathwayLPSmethyltryptophanpig

Identifiers

PMID30279361
PMCPMC6213023
OpenAlexW2895445839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.